Ilmodol Dolori Articolari E Muscolari

Diclofenac epolamine, the active ingredient in Ilmodol Dolori Articolari E Muscolari, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as a topical formulation for external use. It relieves joint, muscle and arthritic pain in adult patients, reducing inflammation at the site of application.

GNH USA supplies Ilmodol Dolori Articolari E Muscolari as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac epolamine is a topical NSAID used to manage pain and inflammation in musculoskeletal conditions.

- Joint (articular) pain: reduces inflammation and alleviates discomfort in affected joints. - Muscle pain: eases soreness and stiffness in strained or over‑used muscles. - Arthritic pain: diminishes swelling and pain associated with osteoarthritis and rheumatoid arthritis.

Topical diclofenac may cause skin‑related reactions and, rarely, systemic adverse events.

Common Side Effects: - Skin irritation: redness, itching or burning at the application site. - Dryness or peeling of the skin. - Localized rash or mild swelling.

Serious or Rare Side Effects: - Severe allergic reactions: hives, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Systemic NSAID effects: gastrointestinal bleeding, renal impairment, or cardiovascular events.

When using Ilmodol, consider the following safety measures.

- Assess skin integrity: avoid application on broken, infected or inflamed skin. - Limit area of application: do not exceed the recommended surface area per dose. - Monitor for systemic signs: watch for unexplained stomach pain, blood in stool, or swelling. - Use with caution in elderly: increased susceptibility to NSAID‑related adverse events. - Avoid concurrent systemic NSAIDs: higher risk of gastrointestinal and renal complications. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Diclofenac epolamine may interact with other medicines, altering safety or efficacy.

Major Interactions (Avoid): - Systemic NSAIDs: increased risk of gastrointestinal bleeding and renal toxicity. - Anticoagulants (e.g., warfarin): heightened bleeding tendency. - Lithium: potential for elevated lithium serum levels. - Methotrexate: enhanced methotrexate toxicity. - Other COX‑2 inhibitors: additive cardiovascular risk.

Moderate Interactions (Monitor Closely):\n- Diuretics: possible reduction in renal function. - ACE inhibitors or ARBs: may impair renal perfusion. - Corticosteroids: increased gastrointestinal ulcer risk. - SSRIs or SNRIs: additive bleeding risk. - Antihypertensives (especially potassium‑sparing): monitor electrolytes.